Could a common antibiotic spare Last-Resort drugs for ICU lung infections?
NCT ID NCT04276480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a common antibiotic (piperacillin-tazobactam) could effectively treat ventilator-associated pneumonia in ICU patients who carry resistant bacteria in their gut. The goal was to see if this approach could reduce the need for stronger, last-resort antibiotics called carbapenems. Only 9 patients were enrolled, and the study measured survival and infection recovery rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTEROBACTERIACEAE INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier de la Côte Basque
Bayonne, 64100, France
-
Hopital Pellegrin
Bordeaux, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Probiotics join the fight against superbugs in the gut
- Superbug sleuths decode the DNA of drug-resistant e. coli to stop its spread
- Poop pills vs. superbugs: can a fecal transplant beat resistant gut bacteria?
- Superbug outbreak in ICU during COVID: lessons learned
- Poop pills vs. superbugs: can a fecal transplant clear Drug-Resistant bacteria?
- ICU superbug study reveals resistance patterns